FIELD: medicine.
SUBSTANCE: invention relates to the use of an inhibitor of dipeptidyl peptidase-3 (hereinafter – DPP3) activity for the treatment of a disease or condition accompanied or related to necrotic processes in an individual. The inhibitor of DPP3 activity is an anti-DPP3 antibody, a fragment of an anti-DPP3 antibody or scaffold protein, other than Ig, against DPP3, which bind to SEQ ID NO:1 or SEQ ID NO:2. The disease is selected from a group including heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, microbial infection, AIDS, malaria, SIRS, sepsis, cancer, acute kidney failure (AKI), seizures, neurodegenerative diseases, autoimmune diseases, vascular diseases and hypotension.
EFFECT: invention provides for the treatment of a disease or condition in an individual accompanied or related to necrotic processes, using an inhibitor of DDP3 activity.
5 cl, 12 tbl, 11 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND MATERIALS FOR ASSESSMENT OF RESPONSE TO THERAPY AGAINST PLASMA-BLASTS AND PLASMA CELLS | 2017 |
|
RU2787629C2 |
| HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | 2018 |
|
RU2781116C1 |
| FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2774368C2 |
| ANTIBODIES SPECIFIC TO MMP9 | 2015 |
|
RU2714043C2 |
| INHIBITORY PATHWAY NEUTRALIZATION IN LYMPHOCYTES | 2017 |
|
RU2769569C2 |
| PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| ANTIBODY AGAINST ADRENOMEDULLIN (ADM), OR FRAGMENT OF ANTI-ADM ANTIBODY, OR ANTI-ADM NON-IG FRAME FOR USE IN INTERVENTION AND THERAPY OF HYPEREMIA IN PATIENT | 2017 |
|
RU2762059C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
